NOXXON Pharma AG is an independent biopharmaceutical company focusing on the development of innovative pharmaceutical products based on its unique proprietary Spiegelmer® Technology
NOXXON Pharma AG is an independent biopharmaceutical company focusing on the development of innovative pharmaceutical products based on its unique proprietary Spiegelmer® Technology. The company is concentrating its attention on inflammatory diseases and haematological conditions. NOXXON’s lead compound, NOX-E36 for treatment of kidney inflammation, is currently undergoing phase I clinical testing.